experience with direct acting antiviral agents for treating hepatitis c virus infection in renal transplant recipients in recent past directacting antiviral drugs daas have become the standard of care for the treatment of hepatitis c virus hcv infection however the experience with the use of these drugs in indian renal transplant recipients is limited we retrospectively reviewed our experience with daabased treatment for hcv infection in such patients between april 2015 and december 2016 six adults median age 41 range 3452 years male 5 gt1 2 gt3 3 and gt4 1 including three with prior failed interferonbased treatment had received genotypeguided daabased antihcv treatment 1 to 158 median 15 months after renal transplantation of them four completed the planned 24week treatment without any significant adverse event one of them had increase in serum creatinine after 16 weeks of treatment with sofosbuvir and daclatasvir with acute interstitial nephritis on kidney biopsy his renal function improved on stopping the drugs the other patient had preexisting mild renal dysfunction which worsened after 8 weeks of sofosbuvirledipasvir treatment this did not reverse on stopping treatment all the six patients achieved undetectable hcv rna after 4 weeks of treatment and also achieved sustained virologic response ie lack of detectable hcv rna in serum 12 weeks after stopping treatment overall daabased treatment was effective in treating hcv infection in our renal transplant recipients however caution and monitoring of renal function during such treatment is advisable in patients who have additional factors that predispose to renal injury